JuanCRamosMD

Hematology • Miami, FL

Hematologic Oncology

Professor, Medicine, University of Miami School of Medicine

Join to view full profile

Dr. Ramos is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ramos' full profile

Already have an account?

Office
1611 NW 12th Ave
# M851
Miami, FL 33136
Phone+1 305-243-1000

Fax+1 305-243-9927

Education & Training

University of Miami/Jackson Health SystemResidency, Internal Medicine, 1999 - 2001
Rutgers New Jersey Medical SchoolClass of 1999

Certifications & Licensure

FL State Medical License 2003 - 2025

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014

Clinical Trials

Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma Start of enrollment: 2008 Sep 01
Terminated
Phase 1
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma Start of enrollment: 2007 Nov 01
Completed
Phase 1
Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma Start of enrollment: 2007 Nov 01
Terminated
Phase 4
Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas Start of enrollment: 2010 Oct 06
Completed
Phase 1, Phase 2
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection Start of enrollment: 2013 Nov 01
Terminated
Phase 1
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) Start of enrollment: 2012 Jun 01
Completed
Phase 2
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma Start of enrollment: 2009 Apr 21
Terminated
Phase 2
Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias Start of enrollment: 2023 Nov 30
Withdrawn
Phase 1
Roles: Sponsor-Investigator, Contact, Principal Investigator
Trial of Ixazomib for Kaposi Sarcoma Start of enrollment: 2023 Nov 07
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

59 citations
Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors
Soley Bayraktar, Ulas Darda Bayraktar, Juan Carlos Ramos, Alexandra Stefanovic, Izidore S. Lossos
Journal of Neuro-Oncology. 2011-01-01
35 citations
Whole-genome landscape of adult T-cell leukemia/lymphoma.
Yasunori Kogure, Takuro Kameda, Junji Koya, Makoto Yoshimitsu, Kisato Nosaka
Blood. 2021-10-25
18 citations
CADM1 is essential for KSHV-encoded vGPCR-and vFLIP-mediated chronic NF-κB activation.
Richard Hunte, Patricia Alonso, Remy Thomas, Cassandra Bazile, Juan Carlos Ramos
Plos Pathogens. 2018-04-26

Abstracts/Posters

Identifying a Simple Clinical Prognostic Model for Aggressive Adult T-Cell Leukemia/Lymphoma in Latin American Population and Its Validation: A Large International Stu...
Juan Carlos Ramos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085
Juan Carlos Ramos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's Lymphoma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019